China Health : Inside Information of COVID-19 risk of death reduced by 89%, the combi

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA HEALTH GROUP INC.

中 國 醫 療 集 團 有 限 公 司

(Carrying on business in Hong Kong as "萬全醫療集團") (Incorporated in the Cayman Islands with limited liability)

(Stock Code: 08225)

Inside Information of

COVID-19 risk of death reduced by 89%, the combination of ritonavir studied by China Health Group and Pfizer's new drug creates a miracle

On November 5, 2021, science, entitled "Pfizer's good news is the world's good news", reported that Pfizer's combination of anti-virus drugs can reduce high-risk death and hospitalization rate by 89%, while the first officially announced drug of Merck pharmaceutical company, molnupiravir, reduced the hospitalization rate and mortality to 50%. Pfizer's shares rose 10.7% before the recent session.

Pfizer Paxlovid consists of two components: PF-07321332 and ritonavir. Ritonavir is the drug that the Group has participated in research and long-term benefits in previous years. Ritonavir raw material and oral liquid Maikexin have been registered and approved by the SFDA(H20051019), by Wanquan pharmaceutical, an affiliated enterprise.

The Group's RWS Wanquan center has a grand plan, which is to reorganize and group existing medicines through the big data real clinical research, and find a sure card for finding the best treatment. In addition to the discovery of a number of drugs such as ritonavir on New Coronavirus (2019-nCoV), but also including Yue ting and other drugs to reduce the 2019-nCoV death of smokers, as well as the prevention and treatment of depression and allergic reactions brought by the 2019-nCoV.

As for the death rate of COVID-19 nearly 90%, the 2019-nCoV will coexist with humans for a long time, bringing long-term drug demand. It is believed that the

manufacturing of the Group's affiliated enterprises and the Group's continuous clinical research and promotion will bring long-term considerable income to the Company.

China Health Group Inc. is a leading enterprise that, driven by the three cores of the Real World Study, Real World Data and Artificial Intelligence, provides three major services for life sciences, precision digital medical "research-based specialty" CHGmyD services, Real World Study CHGRWS services and the Scientific research product promotion service of reconstructing the trillion dollar drug promotion market CRSO services. The Group focuses on the three century epidemic diseases of brain science, allergy and antiviral, and constructs five specialty brands: baimin Kangmin, Xixin spirit, Xien prevention and treatment of stroke mania, Yuejie smoking addiction , Special viral drugs and rare disease.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company and, in case of doubt, to seek independent advice from professionals or financial advisers.

By order of the Board

China Health Group Inc.

GUO Xia

Chairman

Hong Kong, 7 November 2021

As at the date hereof, the Board comprises two executive Directors, being Mr. GUO Xia and Dr. SONG Xuemei; one non- executive Director, being Mr. SU Yi; and three independent non-executive Directors, being Mr. QIU Rui, Dr. NI Binhui and Mr. ZHEN Ling.This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading. This announcement will remain on the "Latest Listed Company Information" page of the GEM website at http://www.hkgem.com for 7 days from the date of its posting. This announcement will also be posted on the Company's website at http://www.chgi.net.